Pharmacoepidemiological analysis of the consumption of antibacterial drugs i n the Russian Federation in the period 2008–2020


D.D. Ivanova(1), I.I. Temirbulatov(2) , I.N. Sychev(2) , N.B. Lazareva(1), 1-I.M. Sechenov First Moscow State Medical University (Sechenov University), 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation; 2-Russian Medical Academy of Continuing Professional Education, 2/1, Barrikadnaya St., Build. 1, Moscow 125993, Russian Federation

Introduction. Effective and safe pharmacotherapy for infectious diseases is extremely difficult due to the growing resistance of pathogens to available drugs. Due to different resistance mechanisms, the pathogens of the ESKAPE group are a group of dangerous causative agents of nosocomial infectious diseases. Every year, hospitals purchase a large quantity of antibacterial drugs (ABDs), but not all of them are effective against resistant pathogens. The study of the characteristics of the consumption of ABDs in the hospital sector contributes to the rational use of drugs by hospitals. Objective. To study the dynamics, pattern, and regularities of use of J01 subgroup ABDs by hospitals in the Russian Federation in the period 2008-2020. Material and methods. A retrospective pharmacoepidemiological analysis was made for the J01 subgroup ABDs purchased by Russian hospitals in 2008–2020. The analysis was carried out using the data published in the Unified Information System in the field of procurement and in the database of IQVIA Holdings Inc. A separate analysis was done for ABDs that are active against the ESKAPE pathogens. Results. There was an increase in the volume of consumption of J01 subgroup drugs and ABDs that are active against the ESKAPE group. In 2020, the maximum consumption of J01 ABDs was recorded, which is due to the greatest COVID-19 spread. Among the federal districts, the Central Federal District makes the most ABD purchases. Among the analyzed ABDs, the largest quantities of tigecycline, piperacillin + [tazobactam], cefotaxime + [sulbactam] and cefepime + [sulbactam] were purchased for the needs of hospitals in all federal districts of Russia. Conclusion. There was a substantial increase in the consumption of ABDs in both quantitative and value terms. In value terms, there was a fairly large increase in the use of ABDs that are active against the ESKAPE group pathogens.

antibacterial drugs
antimicrobial drugs
ESKAPE pathogens
hospital purchases

  1. De Oliveira D.M.P., Forde B.M., Kidd T.J. et al. Antimicrobial resistance in ESKAPE pathogens. Clin. Microbiol. Rev. 2020; 33: e00181–19. DOI:10.1128/CMR.00181-19
  2. Breijyeh Z., Jubeh B., Karaman R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules. 2020; 25 (6): 1340. DOI:10.3390/molecules25061340
  3. Savintseva D.D., Sychev I.N., Lazareva N.B. Farmakoekonomicheskie issledovanija novyh antibakterial'nyh preparatov, aktivnyh protiv polirezistentnyh vozbuditelej. Farmatsija. 2020; 69 (4): 10–7. DOI: 10/29296/25419218-2020-04-02 [Savintseva D.D., Sychev I.N., Lazareva N.B. Pharmacoeconomic studies of novel antibacterial drugs active againstmultidrug resistant pathogens. Farmatsiya. 2020; 69 (4): 10–7. DOI:10/29296/25419218-2020-04-02 (in Russian)].
  4. Santajit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed. Res. Int. 2016. DOI: 10.1155/2016/2475067.
  5. Rossijskie klinicheskie rekomendatsii. Programma SKAT Strategija kontrolja antimikrobnoj terapii) pri okazanii statsionarnoj meditsinskoj pomoschi. [Elektronnyj resurs]. Rezhim dostupa: https:// [Russian clinical guidelines. SCAT (Antimicrobial Therapy Control Strategy) program for inpatient care. [Electronic resource]. Access mode: https:// (in Russian)]
  6. Edinaja informatsionnaja sistema v sfere zakupok. Ofitsial'nyj sajt. [Elektronnyj resurs]. Rezhim dostupa: https:// www.// [Unified information system in the field of procurement. Official site. [Electronic resource]. Access mode: https:// www.// (in Russian)]
  7. DSM Group. Otchety. [Elektronnyj resurs]. Rezhim dostupa: https:// [DSM Group. Reports. Electronic resource]. Access mode: https:// (in Russian)].
  8. Langford B.J., So M., Raybardhan S. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin. Microbiol. Infect. 2021; 27 (4): 520–31. DOI: 10.1016/j.cmi.2020.12.018
  9. Gong J., Su D., Shang J. et al. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis. Medicine (Baltimore). 2019; 98 (38): e17091. DOI: 10.1097/MD.0000000000017091
  10. Stein G.E., Babinchak T. Tigecycline: an update. Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 331–6. DOI: 10.1016/j.diagmicrobio